Gut Microbiota and Drug-Related Liver Injury: Challenges and Perspectives

• Published in: Advanced gut & microbiome research 2023-01, Vol.2023, p.1-9
• Main Authors: Su, Yuanyuan, Lu, Ning, Li, Qian, Wen, Hua, Zhang, Xiao Qin, Zhang, Mingxin
• Format: Article
• Language: English
• ISSN: 2755-1652; 2755-1652
• DOI: 10.1155/2023/5442597

Drug-related liver injury (DILI) is increasing in the incidence of liver injury due to nonviral liver disease and has become a health problem that should not be underestimated. As a hot research topic in recent years, gut microbiota have been studied in various tumors, cardiovascular metabolic diseases, and human immunity. However, there is still a lack of research related to gut microbiota and DILI. It is known that they can influence each other through the regulation of the “gut-liver axis,” and the relationship between them and the possible mechanisms of action are still at the research stage. Human leukocyte antigen (HLA) gene polymorphisms are closely related to the development of DILI, and the gene can also affect changes in the composition of gut microbes. In this paper, we review the possible relationships and mechanisms between DILI and gut microbiota in order to provide new research directions for the prevention and treatment of DILI in the future. In the future, untargeted therapies using antibiotics, probiotics, or FMT will be replaced by personalised and precision medicine approaches, such as bioengineered bacterial strains or drugs that modulate specific bacterial enzymes and metabolic pathways.